IQVIA HOLDINGS INC.

NYSE: IQV·Research Triangle Park, North Carolina·

Price
$264.73
Base IV
$68.42

Valuation snapshot

Above bull case

At $264.73, the price is above even our bull case of $141.68.

Values per share, from an .

No growth
…
Loading earnings power
Base case
$68.42
26% of the price · range $4.91–$141.68
Price vs base case
287% above
$264.73 against $68.42
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $4.91 to bull $141.68. Values per share.

Price against each value

Bear case
$4.91
Price 5,295% above
No growth
…
—
Base case
$68.42
Price 287% above
Researched bygpt-6-sol
Valuation Oct 28, 2026 · Price as of Nov 16, 2026How we got here

What does Iqvia do?

IQVIA provides life sciences and healthcare companies with clinical research services, commercial analytics, and data infrastructure to accelerate the development and commercialization of medical treatments.

It brought in $17.3B of sales in the 12 months to Sep 2026.

IQVIA clinical research laboratory servicesImage: Iqvia
Industry
Healthcare
Based in
Research Triangle Park, North Carolina
Trades on
NYSE as IQV

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 8¢ was left as profit after every cost, interest and tax. The biggest cost is everything else it takes to operate, 75¢ of every dollar.

  • Sales, marketing and admin12¢
  • Everything else it takes to operate75¢
  • Interest and other costs4¢
  • Tax1¢
  • Left as profit8¢
  • Other items after tax came back in+1¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Iqvia, and for what?

IQVIA sells clinical research services, healthcare data and analytics, software, and commercial support to life sciences and healthcare organizations. It earns revenue by providing these services and solutions; it reports three 2025 business segments, which it reorganized into two segments effective January 1, 2026.

Its customers are mainly pharmaceutical, biotechnology, medical device, and consumer health companies, as well as payers, governments, healthcare providers, distributors, and pharmacies.

  • Research & Development Solutions

    55%

    Clinical research and trial services, including trial management, laboratory work, and patient and site support.

    IQVIA clinical research laboratory servicesImage: Iqvia
  • Technology & Analytics Solutions

    41%

    Healthcare data, analytics, software, consulting, and real-world evidence services.

  • Contract Sales & Medical Solutions

    5%

    Contract sales teams, patient engagement, and medical services for life sciences companies.

    IQVIA contract sales servicesImage: Iqvia
Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Valencia Central Laboratory and Biorepository — Valencia, United States. The 134,000-square-foot facility combines clinical trial testing and biorepository services that support drug development customers.
  • Livingston Central Laboratory — Livingston, United Kingdom. The Livingston facility provides central laboratory testing for clinical trials within IQVIA’s global laboratory network.
  • Beijing Laboratory — Beijing, China. The Beijing facility combines central laboratory, genomics and bioanalytical services for clinical development work.
  • Singapore Central Laboratory — Singapore, Singapore. The Singapore laboratory provides regional clinical trial testing as one of IQVIA Laboratories’ four main central laboratories.
  • Marietta Immunoassay Laboratory — Marietta, United States. This 20,000-square-foot principal immunoassay facility supports high-throughput bioanalysis alongside flow cytometry, cell culture and translational sciences.
See them on the globe

IQVIA Holdings Inc. 2025 Form 10-K, Items 1 and 7

How is the business doing?

Sales grew from $11.4B in 2020 to $16.3B in 2025, about 8% a year.

Running the business leaves about 13¢ of each sales dollar as operating profit, up from 6¢ in 2020.

After paying for its upkeep and new investment, it had $2.1B of cash to spare in the 12 months to Sep 2026.

Sales$16.3B
20162025
Operating margin13%
20162025
Free cash flow$2.1B
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

IQVIA says its mission is to accelerate innovation for a healthier world.

“Accelerate innovation for a healthier world”

IQVIA 2024 Proxy Statement

What management says it is working on now:

2026 revenue, 2026
$17.275 billion to $17.475 billion
IQVIA Reports Second-Quarter 2026 Results
2026 adjusted EBITDA, 2026
$4.000 billion to $4.050 billion
IQVIA Reports Second-Quarter 2026 Results
2026 adjusted diluted earnings per share, 2026
$12.80 to $13.00
IQVIA Reports Second-Quarter 2026 Results
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is holding steady. In Q3 2026 it sold 8% more than a year earlier. The year before, quarters averaged 8%.

Its operating margin is about where it was a year ago, 13¢ per sales dollar.

Since Oct 2026 the share price has fallen 4%, from $275.07 to $264.73.

Bull $141.68Base $68.42Bear $4.91Oct 30Nov 16 · $264.73
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

Our own estimate moved too: the base case went from $62.31 to $68.42 a share between our last two valuations.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Clinical research contracts may be delayed or canceled

    Clients can end many research contracts on short notice, for example after trial setbacks, funding changes, or shifts to competitors. Delays or cancellations can reduce revenue and leave resources underused.

    From the company's own filingsWould hit how fast sales growIQVIA Holdings Inc. 2025 Form 10-K, Item 1A: Risk Factors

  2. Access to outside data could be restricted

    IQVIA relies on third-party suppliers for data used in some information services. Suppliers could raise prices, limit permitted uses, provide lower-quality data, or stop supplying it, affecting the company's ability to serve clients.

    From the company's own filingsWould hit how fast sales growIQVIA Holdings Inc. 2025 Form 10-K, Item 1A: Risk Factors

  3. Privacy rules may limit data use

    Privacy and data-protection laws can restrict how IQVIA collects, uses, and transfers health information. New rules or compliance failures could require added spending or limit some services.

    From the company's own filingsWould hit how fast sales growIQVIA Holdings Inc. 2025 Form 10-K, Item 1A: Risk Factors

  4. Cyberattacks could disrupt services or expose information

    A security breach at IQVIA or a vendor could interrupt operations, expose sensitive data, trigger legal or regulatory costs, and damage trust with clients and data suppliers.

    From the company's own filingsWould hit how fast sales growIQVIA Holdings Inc. 2025 Form 10-K, Item 1A: Risk Factors

  5. Competition and technology changes could pressure growth

    IQVIA competes with large service and technology firms, clinical research organizations, client in-house teams, and new entrants. If it fails to adapt or clients do less outsourcing, demand and growth could weaken.

    From the company's own filingsWould hit how fast sales growIQVIA Holdings Inc. 2025 Form 10-K, Item 1A: Risk Factors

  6. Transformation efforts may not deliver expected savings

    The company is changing technology and processes to improve productivity and reduce costs. If these efforts are delayed or do not achieve their goals, its competitiveness and operating results could suffer.

    From the company's own filingsWould hit how much of each sale it keepsIQVIA Holdings Inc. 2025 Form 10-K, Item 1A: Risk Factors

  7. Management attributes 0.025 of 2026 revenue growth to acquisitions, which limits what current reported growth says about continuing demand.

    From our researchWould hit how fast sales growIQVIA Q3 2026 results

  8. Acquisition spending was 1.714 billion dollars in 2025, substantially above the 589 million dollars spent in the first nine months of 2026, making a stable rate uncertain.

    From our researchWould hit how much it has to reinvestIQVIA 2025 results

Is it a good business?

From 2016 to 2025 it earned between 3% and 10% on the capital invested in it, a median of 5%. Its cost of capital in the latest valuation is 8.6%; returns were above it in 4 of the 10 years.

From 2016 to 2025 it earned between 1% and 23% on its shareholders' equity, a median of 16%.

Over 10 years its operating margin ranged from 6¢ to 14¢ per sales dollar, a median of 10¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital9%
20162025

Cost of capital 8.6%

Return on equity21%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 18%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 2.7% in a year, so each remaining share owns a slightly bigger slice.

It owes $13.6B more than it holds in cash, about 6.1 years of operating profit.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $264.73. Our put its value between $4.91 and $141.68, with $68.42 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $4.91

Despite faster sales this year, clinical work grows more slowly, costs take a larger share of revenue, and expansion uses more cash.

Base case, $68.42

After this year's faster sales, clinical work keeps the business growing while profits recover modestly and expansion continues.

Bull case, $141.68

This year's faster sales turn into lasting gains as more clinical work arrives, while the business keeps more profit from each sale.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects far more than we do.Price above value: 287%

For Iqvia to be worth today's $264.73, sales would need to grow about 27.2% a year. We assume 6.0%. Over the last 5 years, sales grew 5.0% a year.

−10%0%+10%+20%+30%+40%Past 5 yrs 5.0%We assume 6.0%Price needs 27.2%

Or, if sales grow 6.0% as we assume, the price works with a profit margin of 31.2% (we assume 13.5%).

Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.

Do you think sales can grow 27.2% a year?

Try your own numbers

We're not very sure of this range: it scores 48 out of 100 on our checks. The weakest point is scenario dispersion.

Test the assumptions

Our base value of $68.42 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average6.0%
  • Operating margin13.5%
  • Long-term growth rate2.2%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$68.42 -74.2%

Build